Industry news that matters to you.  Learn more

Caliper Life Sciences to Aquire Cambridge Research & Instrumentation

Reading time: 1 – 2 minutes

Caliper Life Sciences has announced that it has entered into definitive agreement to aquire privately-held Cambridge Research & Instrumentation (CRi) for approximately $20.0 million.

CRi’s patented preclinical and tissue-based multiplexed analysis systems will boost Caliper’s discovery biomarker and personalized medicine development offerings.

Kevin Hrusovsky, President and CEO of Caliper Life Sciences, said:

The acquisition extends the reach of Caliper’s proprietary offerings along the in vitro to in vivo bridge by filling the gap in tissue analysis platforms. Similar to the approach we used in our successful commercialization of other disruptive technologies such as microfluidic LabChips and whole animal optical imaging systems, we see an opportunity to leverage CRi’s advanced multiplex technology towards unmet needs in a rapidly changing market, in this case the billion-dollar tissue imaging and digital pathology clinical research market. With CRi’s technologies in our toolkit, we will be able to offer a more comprehensive suite of tools and services to address the important emerging trend toward personalized medicine.

CRi’s heaadquarters and manufacturing operations will be consolidated with Caliper’s existing operations in Hopkinton, Mass. in 2011. Approximately 75% of CRi’s 49 employees will be offered continuing employment with Caliper.

Source: Caliper Life Sciences